FOLD - Amicus Therapeutics Inc. (FOLD) Q1 2024 Earnings Call Transcript
2024-05-09 15:14:15 ET
Amicus Therapeutics, Inc. (FOLD)
Q1 2024 Earnings Conference Call
May 9, 2024 08:30 AM ET
Company Participants
Andrew Faughnan - VP, IR
Bradley Campbell - President and CEO
Sebastien Martel - CBO
Jeff Castelli - CDO
Simon Harford - CFO
Conference Call Participants
Anupam Rama - JPMorgan
Ellie Merle - UBS
Kristen Kluska - Cantor Fitzgerald
Tazeen Ahmad - Bank of America
Presentation
Operator
Good morning ladies and gentlemen and welcome to the Amicus Therapeutics' First Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that. As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host Mr. Andrew Faughnan, Vice President of Investor Relations. You may begin.
Andrew Faughnan
Thank you, Jill. Good morning. Thank you for everyone. Thank you for joining our conference call to discuss Amicus Therapeutics' first quarter 2024 financial results and corporate highlights.
Leading today's call we have Bradley Campbell, President and Chief Executive Officer; Sebastien Martel, Chief Business Officer; Simon Harford, Chief Financial Officer; and Dr. Jeff Castelli, Chief Development Officer. Joining for Q&A is Dr. Mitchell Goldman, Chief Medical Officer; and Ellen Rosenberg, Chief Legal Officer.
As referenced on Slide 2, we might make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business as well as our plans and prospects.
Our forward-looking statements should not be regarded as representation by us and any of our plans will be achieved. Any or all the forward-looking statements made on this call may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties.
You are cautioned not to place undue reliance on any forward-looking statements, which speak only to the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this presentation and conference call to reflect events or circumstances after the date hereof....
Amicus Therapeutics, Inc. (FOLD) Q1 2024 Earnings Call Transcript